Objectives: Inflammatory bowel disease (IBD) is a chronic inflammatory disorder. Previous studies have suggested that chronic systemic inflammation increases the risk of Parkinson's disease (PD). This study examined the effects of IBD on the development of PD. Using univariable and multivariable Cox proportion hazard regression models, we estimated the adjusted hazard ratio (aHR) for PD with a 95% confidence interval (CI) with adjustment for age, sex, and comorbidities.
P
arkinson's disease (PD), a movement disorder, results from a loss of dopaminergic neurons and typically develops between the ages of 55 and 65 years and occurs in up to 1% of people aged 60 years and above. 1 Patients with PD typically display motor symptoms including rest tremors, rigidity, bradykinesia, and a stooping posture and nonmotor features such as depression, anxiety, dementia, and autonomic dysfunction. The cause of PD remains unknown, but the risk of developing PD is a complex interplay of genetic and environmental factors affecting numerous fundamental cellular processes. 2 Inflammatory bowel disease (IBD) comprises 2 types of chronic intestinal disorders, Crohn's disease (CD) and ulcerative colitis. The prevalence of IBD is at least 0.4% in Europe and North America 3 and is increasing in many parts of the Asia-Pacific area. 4, 5 CD generally involves the ileum, colon, or any region of the intestine in a discontinuous transmural pattern, whereas ulcerative colitis involves the rectum to the pancolitis in an uninterrupted pattern with typical confinement to the mucosa. Patients with IBD are at risk of primary sclerosing cholangitis, ankylosing spondylitis, and psoriasis. Suspicion of IBD is higher in patients with persistent or recurrent abdominal pain, diarrhea, rectal bleeding, weight loss, or anemia. Endoscopic evaluation with histopathological sampling is generally considered indispensable. 6, 7 PD and IBD are chronic disorders with shared key inflammatory activities implicated in the pathogenesis. Several cytokines, such as interleukin (IL)-1b and tumor necrosis factor (TNF)-a, have been shown to be associated with PD and IBD. 8, 9 Moreover, genetic factors, including polymorphism in the CARD15/NOD2 gene, and LRRK2 mutations have been suggested to be critical risk factors for both PD and IBD. [10] [11] [12] [13] However, no large-scale population-based study has evaluated the association between IBD and PD. Therefore, this study evaluated the risk of PD in a cohort of patients in Taiwan with IBD compared with a non-IBD cohort.
METHODS

Data Source
The National Health Insurance program, implemented in 1995, is a compulsory single-payer health care system with over 99.9% coverage of the 23.22 million residents in Taiwan. 14, 15 The National Health Insurance Research Database (NHIRD) comprehensively includes claims data on both outpatient and inpatient services for nearly the entire population of Taiwan. To ensure the accuracy of disease diagnoses, the National Health Insurance Bureau of Taiwan randomly reviews the medical charts of 1/100 ambulatory and 1/20 inpatient claims. For this study, we used the Longitudinal Health Insurance Database 2000 (LHID 2000), which contains longitudinally linked data on 1,000,000 enrollees (approximately 5% of Taiwan's population) randomly sampled from the 2000 Registry for Beneficiaries of the NHIRD. All personal identifications were encrypted for privacy protection. The International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) was used to identify health statuses. The study was approved by the Institutional Review Board of China Medical University Hospital (CMUH-104-REC2-115).
Sample Participants
Patients aged 20 years or older with newly diagnosed IBD (ICD-9-CM codes 555, 556) were identified for the period of 2000 to 2011 as the IBD cohort. The definition of IBD included ulcerative colitis and Crohn's disease. The first diagnosis date was defined as the index date of IBD. Patients with IBD with a history of PD (ICD-9-CM code 332) before the index date and with incomplete medical information were excluded. Comparison patients aged 20 years or older were selected from people without IBD or a PD history in the LHID 2000. For each identified patient with IBD, 4 comparison patients were randomly identified and frequency-matched with age (each 5-year span), sex, and year of index date for the non-IBD cohort. PD and IBD were diagnosed and coded by specialists according to the standard diagnosed criteria including typical symptoms and signs, laboratory data, and imaging findings. The database used in this study is operated by a single buyer, the government in Taiwan for reimbursement purposes. If these doctors or hospitals make wrong diagnoses or coding, they will be punished with a lot of penalties. Therefore, these data are valid, and the diagnoses of PD and IBD are highly reliable. [16] [17] [18] [19] Outcome and Comorbidity All study patients were followed from the index date to the date of PD diagnosis (ICD-9-CM code 332), date of withdrawal from the insurance system, or the end of 2011, whichever was reached first. The baseline comorbidities considered in this study included diabetes (ICD-9-CM code 250), hypertension (ICD-9-CM codes 401-405), hyperlipidemia (ICD-9-CM code 272), stroke (ICD-9-CM codes 430-438), coronary artery disease (CAD) (ICD-9-CM codes 410-414), head injury (ICD-9-CM codes 850-854, 959.01), depression (ICD-9-CM codes 296.2, 296.3, 300.4, 311), and chronic kidney disease (CKD) (ICD-9-CM code 585).
Statistical Analysis
The baseline characteristics and comorbidities of the IBD cohort and non-IBD cohort were compared. Chi-square and t tests were used to assess the difference in categorical and continuous variables, respectively, between the 2 cohorts. The overall, age-, sex-, and comorbidity-specific incidence density rates (per 1000 person-y) of PD were calculated. Univariable and multivariable Cox proportion hazard regression models were used to examine the effect of IBD on the risk of PD, and the result is shown as a hazard ratio (HR) with a 95% confidence interval (CI). The multivariable models were adjusted for age, sex, and comorbidities of diabetes, hypertension, hyperlipidemia, stroke, CAD, head injury, depression, and CKD. The cumulative incidence of PD between the IBD cohort and non-IBD cohort was analyzed using the Kaplan-Meier method, and the difference was examined using a log-rank test. SAS software (Version 9.3 for Windows; SAS Institute Inc., Cary, NC) was used for all data analyses, with P , 0.05 being considered significant for a 2-tailed test.
RESULTS
Overall, 41,865 patients were selected for this retrospective cohort study, including 8373 patients with IBD and 33,492 non-IBD controls. The age and sex distribution was similar in both cohorts. More than 50% of the patients were younger than 49 years, and more female patients were present in our study. Compared with patients without IBD, patients with IBD had a higher prevalence of comorbidities including hypertension, hyperlipidemia, CAD, head injury, depression, and CKD ( Table 1 ). The mean follow-up period for the patients in the IBD and non-IBD cohorts were 7.30 (SD ¼ 3.14) and 7.13 (SD ¼ 3.18) years, respectively. The cumulative incidence of PD was significantly higher in the patients with IBD (log-rank P ¼ 0.001) than in those without IBD (Fig. 1) .
The overall incidence of PD was 43% higher in the IBD cohort than in the non-IBD cohort ( The relative risk of PD in the age-specific IBD and non-IBD cohorts was significantly higher for patients older than 65 years (aHR ¼ 1.39, 95% CI ¼ 1.07-1.81) ( Table 3 ). When stratified by sex, male patients with IBD had significantly higher risks of developing PD compared with male patients without IBD (aHR ¼ 1.46, 95% CI ¼ 1.07-1.98). The comorbidity-specific analyses showed that patients with IBD with comorbidity had a significantly higher risk of PD compared with patients without IBD with comorbidity (aHR ¼ 1.44, 95% CI ¼ 1.13-1.83). When stratified by follow-up duration, compared with the non-IBD cohort, the IBD cohort exhibited a significantly higher risk of developing PD in the first 2 years of follow-up (aHR ¼ 1.52, 95% CI ¼ 1.00-2.29) and in more than 2 years of follow-up (aHR ¼ 1.31, 95% 
DISCUSSION
This nationwide cohort study of 8373 patients with IBD showed a 35% increase in the risk of PD in patients with IBD compared with patients without IBD in the population of Taiwan. Moreover, among patients with IBD, patients with CD exhibited a higher risk of developing PD (Table 4 ). Based on our research, the risk of PD after a diagnosis of IBD has not been assessed in a nationwide cohort of patients with IBD. We obtained information on diagnoses of PD and IBD, which are known to be highly accurate and almost complete in the NHIRD because all insurance claims are scrutinized by medical reimbursement specialists and undergo peer review.
The male patients with IBD had a slightly higher risk of PD than that of the female patients. A possible explanation for this finding could be the neuroprotective effects of estrogens, but their role remains controversial. 20 We suggest that hypertension and CAD are independent risk factors for PD in patients with IBD. Previous studies have indicated a significantly increased risk of CAD and hypertension among patients with IBD compared with matched controls. 21 However, the relationship between PD and hypertension or CAD remains unclear. Finally, depressive disorders and depressive symptoms are common in both PD 22 and IBD, 23 especially in CD 24 possibly because of a link between inflammatory immune responses and the occurrence of depression in patients with PD and those with IBD. [24] [25] [26] The mechanism of PD development in patients with IBD is probably associated with a dysfunction of the immune system, particularly an innate neuroinflammatory response, through the release of proinflammatory cytokines as a potential etiologic factor. 8, 27 The immunological alterations in patients with PD have been suggested to involve both regional (microglia) and systematic (peripheral) immunity, including increased levels of autoantibodies, although more evidence is required to conclude whether PD is an autoimmune disease. [27] [28] [29] Moreover, the proinflammatory cytokine profile observed in patients with PD, namely an increase in the expression of TNF-a and IL-1b, is strikingly identical to that observed in patients with IBD. 9 The importance of TNF-a and IL-1b signaling in mediating inflammation has been shown in IBD pathogenesis. Hence, our findings indicate the possible existence of common underlying immunological mechanisms between PD and IBD.
Braak et al 30 suggested that the appearance of a-synucleinpositive Lewy pathology initially occurs in both the enteric nervous system and dorsal motor nucleus of the vagus in the earliest stage of PD, and PD may be produced by a hitherto environmental pathogen that breaches the intestinal epithelial barrier. This would allow the putative neurotropic agent to enter terminal axons of the submucosal plexus, initiating PD pathology that would further spread to the central nervous system through the vagal preganglionic innervation of the gut. This evidence suggested a key role of both inflammation and enteric glial cells in maintaining intestinal epithelial barrier integrity 31 and an increase in intestinal epithelial barrier permeability in patients with PD, 32 and indicated the correlation between gastrointestinal inflammation and PD. 33 It is therefore tempting to suggest a link between IBD and PD by our large-scale epidemiological study.
An alternative explanation for the increased risk of PD is genetic susceptibility. Data from genetic studies further support this concept. Single-nucleotide polymorphisms in the CARD15/ NOD2 gene known to be associated with CD are overexpressed in white and Chinese patients with PD. 11, 12, 34, 35 CARD15/NOD2 is a member of the CED/APAF 1 superfamily of apoptosis inducers or enhancers expressed in monocytes and involved in the activation of NF-kB by the bacterial component muramyl dipeptide. 36 The variants have been considered to share a common molecular mechanism of the uncontrolled activation of NF-kB, which is activated both in the dopaminergic neurons of the substantia nigra in patients with PD 37 and in the mononuclear cells of the intestinal lamina propria in patients with CD. 38 Moreover, the LRRK2 gene has been identified by genome-wide association studies as being encoded by a major susceptibility gene for CD. 10 LRRK2 is highly expressed in human peripheral blood mononuclear cells and macrophages and is upregulated by interferon g (INF-g), and its expression is increased by exposure to microbial structures or viral particles, which strongly suggests a role in immune response pathways. 39, 40 The mechanistic role of mutations in the LRRK2 gene in PD remains unclear; however, it was proposed that the detrimental effects mediated by PD LRRK2 mutations may initiate in the periphery and extend to the central nervous system as a consequence of increased levels of proinflammatory factors permeable to the blood-brain barrier. 41 According to the aforementioned evidence, IBD has considerable genetic associations with PD. This study has several limitations. First, information on both exposure (IBD) and outcome (PD) was retrieved from the NHIRD, leading to the risk of ascertainment bias. This approach increases the possibility of falsely high associations. Second, unlike prospective studies, a retrospective cohort study design is subject to biases related to confounder adjustments. Although this was a carefully designed study with adequate controls, potential bias remains because the NHIRD does not provide detailed information on smoking status, alcohol consumption, coffee consumption, physical activity, socioeconomic status, occupation, or family history of PD, which are all potential confounding factors relevant to this study. Moreover, data regarding individual pathological, imaging, and laboratory data, which are necessary to survey the severity of IBD and PD, are not available in the study. Finally, the lack of drug data, such as those for IBD medications, may have also influenced the primary outcomes in our study.
In conclusion, our study suggests that patients with IBD were associated with an increased risk of PD, which was most pronounced in the patients with CD. This association may be explained by chronic inflammation with shared immunological features between PD and IBD. The results may reflect an underappreciated effect of IBD treatment on the risk of PD. Patients with IBD should be aware of the potential risk for PD development.
